|
Gene: SPANXC |
Gene summary for SPANXC |
Gene summary. |
Gene information | Species | Human | Gene symbol | SPANXC | Gene ID | 64663 |
Gene name | SPANX family member C | |
Gene Alias | CT11.3 | |
Cytomap | Xq27.2 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9NY87 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64663 | SPANXC | ATC09 | Human | Thyroid | ATC | 7.62e-19 | 1.77e+00 | 0.2871 |
64663 | SPANXC | ATC1 | Human | Thyroid | ATC | 3.66e-21 | 1.99e+00 | 0.2878 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPANXC | SNV | Missense_Mutation | novel | c.40N>A | p.Val14Ile | p.V14I | Q9NY87 | protein_coding | tolerated(0.05) | benign(0.104) | TCGA-A6-5657-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD |
SPANXC | SNV | Missense_Mutation | novel | c.133T>C | p.Ser45Pro | p.S45P | Q9NY87 | protein_coding | tolerated_low_confidence(0.06) | probably_damaging(0.995) | TCGA-G4-6586-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPANXC | SNV | Missense_Mutation | rs781891014 | c.160N>T | p.Arg54Cys | p.R54C | Q9NY87 | protein_coding | tolerated_low_confidence(0.19) | benign(0.007) | TCGA-NH-A8F7-06 | Colorectum | NA | NA | NA | NA | NA | NA | NA |
SPANXC | SNV | Missense_Mutation | novel | c.182N>T | p.Arg61Ile | p.R61I | Q9NY87 | protein_coding | tolerated_low_confidence(0.18) | benign(0.012) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SPANXC | SNV | Missense_Mutation | rs781862303 | c.218G>A | p.Arg73Gln | p.R73Q | Q9NY87 | protein_coding | tolerated(0.24) | probably_damaging(0.992) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPANXC | SNV | Missense_Mutation | rs782310706 | c.20N>T | p.Ala7Val | p.A7V | Q9NY87 | protein_coding | tolerated(0.16) | benign(0.006) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPANXC | SNV | Missense_Mutation | novel | c.33N>T | p.Lys11Asn | p.K11N | Q9NY87 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
SPANXC | SNV | Missense_Mutation | rs782653522 | c.22N>A | p.Gly8Ser | p.G8S | Q9NY87 | protein_coding | tolerated(0.33) | benign(0.007) | TCGA-EY-A1GK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPANXC | SNV | Missense_Mutation | rs201591692 | c.256N>A | p.Glu86Lys | p.E86K | Q9NY87 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.973) | TCGA-DD-AACI-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
SPANXC | SNV | Missense_Mutation | novel | c.40N>T | p.Val14Phe | p.V14F | Q9NY87 | protein_coding | deleterious(0.01) | possibly_damaging(0.655) | TCGA-44-7661-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |